 REHOVOT, Israel and WILMINGTON, Del., April 21, 2021 GLOBE NEWSWIRE -- Ayala Pharmaceuticals, Inc. Nasdaq: AYLA, a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced the dosing of the first patient in the ongoing Phase 1 clinical trial evaluating its potent investigational gamma secretase inhibitor GSI, AL102, in combination with Novartis investigational anti-B-cell maturation antigen BCMA agent, WVT078, for the treatment of patients with relapsed andor refractory multiple myeloma MM. 